Literature DB >> 30545959

Triple therapy trials in COPD: a precision medicine opportunity.

Samy Suissa1, Amnon Ariel2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30545959     DOI: 10.1183/13993003.01848-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

Review 1.  [Chronic obstructive pulmonary disease: the right treatment for the right patient].

Authors:  Horst Olschewski; Roland Buhl; Georg Christian Funk; Arschang Valipour; Claus F Vogelmeier
Journal:  Internist (Berl)       Date:  2021-04-16       Impact factor: 0.743

Review 2.  ERS International Congress, Madrid, 2019: highlights from the Respiratory Infections Assembly.

Authors:  Cristina Calarasu; Kiarina D Chichirelo-Konstantynovych; Stefan Frent
Journal:  ERJ Open Res       Date:  2020-05-11

3.  Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD.

Authors:  Nicola A Hanania; Alberto Papi; Antonio Anzueto; Fernando J Martinez; Kimberly A Rossman; Christy S Cappelletti; Elizabeth A Duncan; Jack S Nyberg; Paul M Dorinsky
Journal:  ERJ Open Res       Date:  2020-04-27

Review 4.  Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Pulm Ther       Date:  2019-11-02

5.  Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited.

Authors:  Peter Calverley
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

6.  Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.

Authors:  Fernando J Martinez; Klaus F Rabe; Gary T Ferguson; Jadwiga A Wedzicha; Dave Singh; Chen Wang; Kimberly Rossman; Earl St Rose; Roopa Trivedi; Shaila Ballal; Patrick Darken; Magnus Aurivillius; Colin Reisner; Paul Dorinsky
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

7.  A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.

Authors:  Marc Miravitlles; Katia Verhamme; Peter M A Calverley; Michael Dreher; Valentina Bayer; Asparuh Gardev; Alberto de la Hoz; Jadwiga Wedzicha; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-03-11

8.  Effectiveness of Xin Jia Xuan Bai Cheng Qi Decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol for a multicentre, randomised, controlled trial.

Authors:  Jin Jin; Hongchun Zhang; Demin Li; Yue Jing; Zengtao Sun; Jihong Feng; Hong Zhang; Yan Zhang; Tianhong Cui; Xiang Lei; Jing Zhang; Qijian Cheng; Erran Li
Journal:  BMJ Open       Date:  2019-11-28       Impact factor: 2.692

9.  Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?

Authors:  Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 21.405

10.  Mortality in IMPACT: Confounded by Asthma?

Authors:  Samy Suissa
Journal:  Am J Respir Crit Care Med       Date:  2020-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.